Cargando…
Effect of GNAQ alteration on RANKL-induced osteoclastogenesis in human non-small-cell lung cancer
AIMS: Receptor activator of nuclear factor-κB ligand (RANKL) is a key molecule that is expressed in bone stromal cells and is associated with metastasis and poor prognosis in many cancers. However, cancer cells that directly express RANKL have yet to be unveiled. The current study sought to evaluate...
Autores principales: | Choi, Ji-Yoon, Lee, Yun Sun, Shim, Da Mi, Seo, Sung Wook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229297/ https://www.ncbi.nlm.nih.gov/pubmed/32435453 http://dx.doi.org/10.1302/2046-3758.91.BJR-2019-0085.R2 |
Ejemplares similares
-
GNAQ knockdown promotes bone metastasis through epithelial-mesenchymal transition in lung cancer cells
por: Choi, Ji-Yoon, et al.
Publicado: (2021) -
Follicle-Stimulating Hormone Does Not Impact RANKL-Induced Osteoclastogenesis
por: Zhou, Ziyue, et al.
Publicado: (2021) -
Auraptene ameliorates osteoporosis by inhibiting RANKL/NFATc1 pathway-mediated bone resorption based on network pharmacology and experimental evaluation
por: Kim, Mi H., et al.
Publicado: (2022) -
Complete abrogation of key osteoclast markers with a membrane-anchored tissue inhibitor of metalloproteinase: a novel approach in the prevention of osteoclastogenesis
por: Zhang, Yihe, et al.
Publicado: (2022) -
LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway
por: Chen, Xiaojun, et al.
Publicado: (2021)